Quinoline RAGE Modulators, New York University, Apr 23
Summary
New York University filed patent application US20260109684A1 on September 27, 2023, covering quinoline compounds as modulators of RAGE (Receptor for Advanced Glycation End-products) activity. The published application discloses pharmaceutical compositions and dosage forms containing these quinoline compounds for preventing and treating conditions including diabetes complications, inflammation, neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease, and COVID-19 complications. The application names Ann Marie Schmidt, Michaele Maningrasso, Ravichandran Ramasamy, Alexander Shekhtman, and Robert DeVita as inventors.
“Quinoline compounds are disclosed that have a formula represented by the following; and wherein Cy, R1, R4a, R4b, and n are as described herein.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 223 changes logged to date.
What changed
New York University filed patent application US20260109684A1 disclosing quinoline compounds that modulate RAGE (Receptor for Advanced Glycation End-products) activity. The application covers pharmaceutical compositions and dosage forms containing these compounds for therapeutic use across multiple indication areas.
Pharmaceutical companies and researchers developing RAGE-targeted therapies should review the patent claims for potential freedom-to-operate implications. The broad claim scope covering multiple therapeutic applications may affect competitive programs targeting similar mechanisms for diabetes complications, inflammation, neurodegeneration, or cardiovascular disease.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF
Application US20260109684A1 Kind: A1 Apr 23, 2026
Assignee
NEW YORK UNIVERSITY
Inventors
Ann Marie SCHMIDT, Michaele MANIGRASSO, Ravichandran RAMASAMY, Alexander SHEKHTMAN, Robert DEVITA
Abstract
Quinoline compounds are disclosed that have a formula represented by the following; and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as compositions, e g., pharmaceutical compositions, or as dosage forms, e.g., pharmaceutical dosage forms, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease, COVID-19 complications, and other diseases related to RAGE activity.
CPC Classifications
C07D 401/10 A61K 31/5377 A61P 17/02 C07D 215/48 C07D 401/04
Filing Date
2023-09-27
Application No.
19116027
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.